All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Medarex shares plummeted Wednesday as partner Pfizer Inc. unexpectedly halted a Phase III trial of potential melanoma treatment tremelimumab. (BioWorld Today)
